Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3

Phase 2positiveEloraTZPZepboundPositive

AI Analysis

Summary

Eli Lilly's EloraTZP, a combination of an amylin asset and obesity drug Zepbound, achieved all primary and secondary endpoints in Phase 2 trials for obesity and type 2 diabetes, with Phase 3 planned before year-end 2026.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

Met all primary and secondary endpoints in mid-stage trial of adults with obesity and type 2 diabetes

Importance:7/10

Sentiment:

0.85

obesitytype 2 diabetesweight lossblood sugar controlamylinGIP/GLP-1Phase 3 initiation

Related Companies

$LLY

Read the original article

Published by BioSpace on September 30, 2026 2:16 PM

Read Original